medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2014, Number 3

<< Back Next >>

Rev Invest Clin 2014; 66 (3)

Tubular dysfunction and non-albuminuric renal disease in subjects with type 2 diabetes mellitus

Robles-Osorio ML, Sabath E

Language: English
References: 27
Page: 234-239
PDF size: 152.31 Kb.


ABSTRACT

Introduction. Micro-albuminuria is considered an early marker of glomerular injury in patients with diabetes but it has yet to be determined whether testing for markers of tubular injury can also identify people who are at risk of progressive renal disease. Objective. To evaluate markers of tubular injury and renal characteristics in a sample of community treated type 2 diabetic subjects. Material and methods. We carry-out an assessment of a group of community diabetic patients, anthropometric measures, creatinine clearance, HbA1c, lipid profile, the mean fast serum glucose levels, albuminuria and α1-microglobulin (α1M) urine excretion were evaluated. Results. From 95 included patients, 45.2% had α1M urinary excretion  10 µg/gCr, 23.1% micro-albuminuria, 9.6% macroalbuminuria and 27.2% had a GFR ‹ 60 mL/min. The most important risk factor associated with a1M excretion was fasting glucose level (OR 4.3, 95IC 1.7-11.1 p = 0.001); HbA1c ≥ 8% and age were the most important risk factors associated with GFR ≤ 60 mL/min. Most of patients had uncontrolled glucose levels and 45.1% patients with albuminuria were not receiving any drug with anti-proteinuric effects. Conclusions. Fasting glucose levels was the most important risk factor associated with tubular dysfunction; non-albuminuric presentation of CKD defined as GFR ‹ 60 mL/min was frequent in our population, so is necessary to implement different strategies for surveillance in patients with type 2 diabetes aiming to delay progression to CKD.


REFERENCES

  1. Correa-Rotter R, González-Michaca L. Early detection and prevention of diabetic nephropathy: a challenge calling for Robles-Osorio ML, et al. Tubular dysfunction and non-albuminuric renal disease. Rev Invest Clin 2014; 66 (3): 234-239 239 mandatory action for México and the developing world. Kidney Int Suppl 2005; 98: S69-S75.

  2. Perkins BA, Ficociello LH, Ostrander BE, Silva KH, Weinberg J, et al. Microalbuminuria and the risk for early progressive renal function decline in Type 1 Diabetes. J Am Soc Nephrol 2007; 18: 1353-61.

  3. Mantur M, Kemona H, Dabrowska M, Dabrowska J, Sobolewski S, et al. Alpha1-microglobulin as a marker of proximal tubular damage in urinary tract infection in children. Clin Nephrol 2000; 53: 283-7.

  4. Hong CY, Hughes K, Chia KS, Ng V, Ling SL. Urinary α1-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore. Diabetes Care 2003; 26: 338-42.

  5. Prozialeck WC, Edwards JR. Early biomarkers of cadmium exposure and nephrotoxicity. Biometals 2010; 23: 793-809.

  6. 6 . Park SH, Choi HJ, Lee JH, Woo CH, Kim JH, Han HJ. Highglucose inhibitsrenal proximal tubule cell proliferation andinvolves PKC, oxidative stress, andTGF-beta 1. Kidney Int 2001; 59: 1695-705.

  7. Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A, Mangano DT. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann Intern Med 1998; 128: 194-203.

  8. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR, for the UKPDS Study Group. Risk factors for renal dysfunction in Type 2 Diabetes U.K. Prospective Diabetes Study 74. Diabetes 2006; 55: 1832-9.

  9. Lim SC, Liying DQ, Toy WC, Wong M, Yeoh LY, et al. Adipocytokine zinc α2 glycoprotein (ZAG) as a novel urinary biomarker for normo-albuminuric diabetic nephropathy. Diabet Med 2012; 29: 945-9.

  10. Petrica L, Petrica M, Vlad A, Jianu DC, Gluhovschi G, et al. Proximal tubule dysfunction is dissociated from endothelial dysfunction in normoalbuminuric patients with type 2 diabetes mellitus: a cross-sectional study. Nephron Clin Pract 2011; 118: 155-64.

  11. Conway BR, Manoharan D, Manoharan D, Jenks S, Dear JW. Measuring urinary tubular biomarkers in type 2 diabetes does not addprognostic value beyondestablished risk factors. Kidney Int 2012; 82: 812-8.

  12. Bhavsar NA, Köttgen A, Coresh J, Astor BC. Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM-1) as predictors of incident CKD stage 3: the Atheroesclerosis Risk in Communities. Am J Kidney Dis 2012; 60: 233-40.

  13. Peralta CA, Katz R, Bonventre JV, Sabbisetti V, Siscovick D, et al. Associations of urinary levels of kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) with kidney function decline in the Multi-Ethnic Study of Atheroesclerosis (MESA). Am J Kidney Dis 2012; 60: 904-11.

  14. Fasset RG, Venuthurupalli SK, Cobe GC, Coombes JS, Cooper MA, Hoy WE. Biomarkers in chronic kidney disease: a review. Kidney Int 2011; 80: 806-21.

  15. Petrica L, Vlad A, Petrica M, Jianu CD, Gluhovschi G, et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Res Clin Pract 2011; 94: 22-32.

  16. Rodríguez-Morán M, González-González G, Bermúdez-Barba MV, Medina de la Garza CE, Tamez-Pérez HE, et al. Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double blind, placebo-controlled randomized trial. Clin Nephrol 2006; 66: 3-10.

  17. Bobulescu IA. Renal lipid metabolism and lipotoxicity. Curr Opin Nephrol Hypertens 2010; 19: 393-402.

  18. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003; 348: 2285-93.

  19. Cueto-Manzano AM, Cortés-Sanabria LC, Martínez-Ramírez HR, Rojas-Campos E, Barragán G, et al. Detection of early nephropathy in Mexican patients with type 2 diabetes mellitus. Kidney Int 2005; 68: S40-S45.

  20. Leza-Torres O, Briones-Lara E, González-Madrazo MA, de la Cruz-Martínez MC, Ramos-Dávila E. Microalbuminuria en pacientes con diabetes mellitus tipo 2. Rev Med Inst Mex Seguro Soc 2005; 43: 487-93.

  21. López-Arce G, Espinoza-Peralta D, Hernández-Alarcón A, Arce-Salinas A. Factores asociados con microalbuminuria en pacientes diabéticos tipo 2 no hipertensos. Rev Invest Clin 2008; 60: 4-10.

  22. De Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, et al. Albuminuria, a therapeutic target for cardiovascular protection in Type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-7.

  23. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-32.

  24. Kramer HJ, Nguyen QD, Curhan G, Hsu S. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003; 289: 3273-7.

  25. Cardoso CR, Ferreira MT, Leite NC, Barros PN, Conte PH, Salles GF. Microvascular degenerative complications are associated with increased aortic stiffness in type 2 diabetic patients. Atheroesclerosis 2009; 205: 472-6.

  26. Taniwaki H, Nishizawa Y, Kawagishi T, Ishimura E, Emoto M, et al. Decrease in glomerular filtration rate in Japanese patients with type 2 diabetes is linked to atherosclerosis. Diabetes Care 1998; 21: 1848-55.

  27. Hernández-Romieu AC, Elnecavé-Olaiz A, Huerta-Uribe N, Reynoso-Noverón N. Análisis de una encuesta poblacional para determinar los factores asociados al control de la diabetes mellitus en México. Sal Pub Mex 2011; 53: 34-9.




2020     |     www.medigraphic.com